EU Approves First Drug to Slow Multiple Sclerosis Disability Progression

The European Commission has approved Sanofi's Cenrifki (tolebrutinib), marking the first drug in the European Union specifically approved to slow the progression of secondary progressive multiple sclerosis (SPMS) without relapses.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

24urSlovenian51d ago

Multipla skleroza: EU odobrila prvo zdravilo za upočasnitev invalidnosti

Evropska komisija je odobrila novo zdravilo Cenrifki (tolebrutinib) francoskega farmacevtskega velikana Sanofi za zdravljenje sekundarno napredujoče multiple skleroze (SPMS) brez zagonov bolezni v zadnjih dveh letih. Gre za prvo zdravilo v Evropski uniji, namenjeno posebej upočasnjevanju napredovanja invalidnosti pri tej obliki bolezni, za katero doslej praktično ni bilo učinkovitih terapevtskih možnosti.

Read full article →

PERSPECTA

PERSPECTA

EU Approves First Drug to Slow Multiple Sclerosis Disability Progression

Sources

Multipla skleroza: EU odobrila prvo zdravilo za upočasnitev invalidnosti

Related Stories

Jane Street Suffers $15 Billion Loss in July Due to Market Ructions

Selena Gomez Sued for Alleged Fraud in Mental Health Startup

Nvidia Discloses $21 Billion Stake in SpaceX and $30 Billion in Intel

Consortium Seals $1.9 Billion Investment in Liverpool FC, Amit Bhatia Named Vice-Chairman

PERSPECTA